Corbus Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, focuses on the development and commercialization of various therapeutic products to treat inflammatory and fibrotic diseases. The company's lead product candidate is lenabasum, a synthetic oral endocannabinoid-mimetic drug that is in Phase III clinical trials for the treatment of systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus diseases. Corbus Pharmaceuticals Holdings, Inc. was founded in 2009 and is based in Norwood, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CRBP
CUSIPN/A
Phone617-963-0100
Debt
Debt-to-Equity RatioN/A
Current Ratio7.25
Quick Ratio7.25
Price-To-Earnings
Trailing P/E Ratio-9.31
Forward P/E Ratio-7.47
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.44 million
Price / Sales141.68
Cash FlowN/A
Price / CashN/A
Book Value$1.04 per share
Price / Book5.82
Profitability
EPS (Most Recent Fiscal Year)($0.65)
Net Income$-32,420,000.00
Net Margins-1,040.41%
Return on Equity-76.01%
Return on Assets-64.57%
Miscellaneous
Employees47
Outstanding Shares57,140,000
Corbus Pharmaceuticals (NASDAQ:CRBP) Frequently Asked Questions
What is Corbus Pharmaceuticals' stock symbol?
Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP."
How were Corbus Pharmaceuticals' earnings last quarter?
Corbus Pharmaceuticals (NASDAQ:CRBP) released its quarterly earnings results on Thursday, May, 10th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.10) by $0.11. The biopharmaceutical company had revenue of $0.95 million for the quarter, compared to analyst estimates of $6.25 million. Corbus Pharmaceuticals had a negative return on equity of 76.01% and a negative net margin of 1,040.41%. View Corbus Pharmaceuticals' Earnings History.
What price target have analysts set for CRBP?
3 Wall Street analysts have issued 1 year target prices for Corbus Pharmaceuticals' stock. Their forecasts range from $20.00 to $32.00. On average, they anticipate Corbus Pharmaceuticals' stock price to reach $25.3333 in the next twelve months. View Analyst Ratings for Corbus Pharmaceuticals.
Who are some of Corbus Pharmaceuticals' key competitors?
Some companies that are related to Corbus Pharmaceuticals include Lexicon Pharmaceuticals (LXRX), ImmunoGen (IMGN), Impax Laboratories (IPXL), IMMURON Ltd/S (IMRN), Theravance Biopharma (TBPH), Apellis Pharmaceuticals (APLS), Athenex (ATNX), Arrowhead Pharmaceuticals (ARWR), Zai Lab (ZLAB), Alder Biopharmaceuticals (ALDR), Retrophin (RTRX), Revance Therapeutics (RVNC), Intra-Cellular Therapies (ITCI), Esperion Therapeutics (ESPR) and Eagle Pharmaceuticals (EGRX).
Who are Corbus Pharmaceuticals' key executives?
Corbus Pharmaceuticals' management team includes the folowing people:
- Dr. Yuval Cohen, CEO & Director (Age 43)
- Dr. Mark A. Tepper Ph.D., Co-Founder, Pres & Chief Scientific Officer (Age 61)
- Dr. Barbara White M.D., Chief Medical Officer (Age 68)
- Mr. Sean F. Moran CPA, MBA, CFO & Principal Accounting Officer (Age 60)
- Scott Constantine M.S., Director of Clinical Research & Operations
Has Corbus Pharmaceuticals been receiving favorable news coverage?
Media stories about CRBP stock have been trending somewhat positive on Wednesday, Accern Sentiment reports. The research firm rates the sentiment of press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Corbus Pharmaceuticals earned a media sentiment score of 0.14 on Accern's scale. They also assigned headlines about the biopharmaceutical company an impact score of 47.02 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
Who are Corbus Pharmaceuticals' major shareholders?
Corbus Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.39%), ETF Managers Group LLC (4.30%), IFP Advisors Inc (2.35%), Allianz Asset Management GmbH (0.24%), Allianz Asset Management GmbH (0.24%) and Royal Bank of Canada (0.09%). Company insiders that own Corbus Pharmaceuticals stock include Alan F Holmer, Barbara White, David P Hochman, Sean F Moran and Yuval Cohen. View Institutional Ownership Trends for Corbus Pharmaceuticals.
Which major investors are buying Corbus Pharmaceuticals stock?
CRBP stock was acquired by a variety of institutional investors in the last quarter, including ETF Managers Group LLC, IFP Advisors Inc, BlackRock Inc., Royal Bank of Canada, Barclays PLC, Allianz Asset Management GmbH, Allianz Asset Management GmbH and Cambridge Investment Research Advisors Inc.. Company insiders that have bought Corbus Pharmaceuticals stock in the last two years include Alan F Holmer, Barbara White, David P Hochman, Sean F Moran and Yuval Cohen. View Insider Buying and Selling for Corbus Pharmaceuticals.
How do I buy shares of Corbus Pharmaceuticals?
Shares of CRBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Corbus Pharmaceuticals' stock price today?
One share of CRBP stock can currently be purchased for approximately $6.05.
How big of a company is Corbus Pharmaceuticals?
Corbus Pharmaceuticals has a market capitalization of $348.57 million and generates $2.44 million in revenue each year. The biopharmaceutical company earns $-32,420,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis. Corbus Pharmaceuticals employs 47 workers across the globe.
How can I contact Corbus Pharmaceuticals?
Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The biopharmaceutical company can be reached via phone at 617-963-0100 or via email at [email protected]
MarketBeat Community Rating for Corbus Pharmaceuticals (CRBP)
MarketBeat's community ratings are surveys of what our community members think about Corbus Pharmaceuticals and other stocks. Vote "Outperform" if you believe CRBP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRBP will underperform the S&P 500 over the long term. You may vote once every thirty days.
